Creative Biolabs' Dual-Action Antibody Webinar Ignites Biotech Buzz

June 19, 2025 03:30 PM BST | By EIN Presswire
 Creative Biolabs' Dual-Action Antibody Webinar Ignites Biotech Buzz
Image source: EIN Presswire

Creative Biolabs hosted a webinar about a multi-engager antibody, which heated up the versatile antibody candidate market including bispecifics. SHIRLEY, NY, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- May 22's webinar wasn't just another science talk—it was a mic-drop moment. Researchers worldwide tuned in to watch Generation of a Dual-Function Multi-Engager Antibody for Simultaneous Targeting NK Cells and Tumor Cells, a hot-ticket presentation that put dual-targeting antibodies squarely in the biotech limelight.

With registrations soaring and Q&A stretching past schedule, one thing is clear—multifunctional antibodies are stealing the spotlight.

The Bispecific Boom: Why Dual Targeting is Pharma's Next Big Thing

Move over, monoclonals—bispecific antibodies are reshaping cancer immunotherapy. By binding two targets at once, the "smart missiles" offer a double whammy against hard-to-treat cancers. As of March 2025, more than 600 bispecific candidates are now in clinical trials. Creative Biolabs is riding the wave with its tailor-made platforms, offering tailored design, robust manufacturing, and flexible formatting options for research, preclinical, and IND-stage projects, with the aim of transforming bispecific antibody design from a molecular puzzle into a plug-and-play revolution.

Products That Hit the Sweet Spot

Whether for startups just embarking on the bsAb exploration or pharma giants preparing for the clinic, Creative Biolabs gives a hand by providing custom bispecific antibody development to offer full-spectrum support—from concept to candidate. Researchers can choose from a wide array of platforms tailored to function and format or pick up their favorite from a bank of proprietary reagents of miscellaneous formats.

* Tandem scFv
Extensively used in cancer immunotherapy, the tandem scFv product line covers mainstream research targets, including CD3, PSA, CD30, and CD28 with a close proximity.
Recombinant Anti-CD3 x Anti-PSA Bispecific Antibody (Tandem scFv)
Recombinant Anti-CD3 x Anti-PLAP Bispecific Antibody (Tandem scFv)
Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (Tandem scFv)
Recombinant Anti-CD28 x Anti-CSPG4 Bispecific Antibody (Tandem scFv)

* Tandem Fab
Tandem Fabs are a class of Fab-based bispecific antibody fragments targeting different epitopes, which have monovalent for each antigen specificity and are more thermally stable than the corresponding scFvs.
Recombinant Anti-CD3 x Anti-PSCA Bispecific Antibody (Tandem Fab)
Recombinant Anti-CD3 x Anti-PSA Bispecific Antibody (Tandem Fab)
Recombinant Anti-CD28 x Anti-FOLR1 Bispecific Antibody (Tandem Fab)

* Tandem scFv-Fc
Need stability and Fc-mediated functions? Check out the Tandem scFv-Fc format for plug-and-play versatility. Creative Biolabs supplies such bispecifics presenting 2 + 2 antigen-binding valency and Fc-mediated functions, such as ADCC, ADCP, and long half-life.
Recombinant Anti-CD3 x Anti-PSA Bispecific Antibody (Tandem scFv-Fc)
Recombinant Anti-CD3 x Anti-p97 Bispecific Antibody (Tandem scFv-Fc)
Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD64 Bispecific Antibody (Tandem scFv-Fc)

"Each format is backed by in-house protein engineering, expression optimization, and analytical support," the rep says. "No guesswork, no hold-ups."

Visit https://www.creative-biolabs.com/bsab/ and learn more.

Next Up: A Full Conference Circuit

With the bispecific pipeline expanding fast, Creative Biolabs is hitting the road. Catch their experts at the upcoming events in Season 3 to learn how their bsAb platforms are reshaping the therapeutic frontier:
August 27–29, 2025 | 5th Oligonucleotides for CNS Summit
September 9–11, 2025 | 16th Annual World Bispecific Summit
September 23–25, 2025 | 7th Exosome Based Therapeutic Development Summit

About
For those researchers, whether exploring bispecifics for oncology, autoimmunity, or CNS disorders, Creative Biolabs is ready to help them hit the ground running with peer-recognized technical support and first-rate research tools.

Candy Swift
Creative Biolabs
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next